Table 4. . Tumor biomarkers assessment.

		Whole sample	TACE + B	TACE	p-value (TACE + B vs TACE)	p-value TACE + B diagnosis vs after treatment	p-value TACE diagnosis vs after treatment
CEA (U/ml)	Baseline	250 (8.5–932)	298 (150–438)	250 (8.5–932)	0.203014
Median (range)	1 month	197 (4.9–800)	238.5 (132–157)	208.5 (4.9–800)	0.221778	0.066655	0.000107†
	3 months	180 (38–736)	182 (110–269)	196 (38–736)	0.093944	0.074979	0.000496†
	6 months	96 (5.1–436)	80 (40–96)	110 (5.1–436)	0.121733	0.057249	0.022245†
CA19-9 (kU/l)	Baseline	230 (24–436)	197 (70–348)	182 (24–436)	0.388423
Median (range)	1 month	187.5 (17–378)	147 (70–259)	178 (17–378)	0.471428	0.027662†	0.10505
	3 months	150 (25–925)	85 (40–150)	206 (25–925)	0.0456†	0.034715†	0.325877
	6 months	93 (20–1259)	40 (25–278)	90 (20–1259)	0.17702	0.022483†	0.3444

^†p < 0.05.

B: Bevacizumab; TACE: Transarterial chemoembolization.